(Q31035390)

28 June 2017

Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data (English)

1 reference

28 June 2017

1 reference

4

David Jones

1 reference

28 June 2017

Lois Lamerato

1

1 reference

28 June 2017

Suzanne Havstad

series ordinal

2

1 reference

28 June 2017

Sanjay Gandhi

series ordinal

3

1 reference

28 June 2017

David Nathanson

series ordinal

5

1 reference

28 June 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

28 June 2017

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

28 June 2017

106

1 reference

28 June 2017

9

1 reference

28 June 2017

1875-1882

1 reference

Breast cancer management: quality-of-life and cost considerations

28 June 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Counting the costs of cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Estimating the treatment costs of breast and lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Adjuvant treatment for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21824

7 January 2021

Identifiers

DOI

10.1002/CNCR.21824

1 reference

28 June 2017

1 reference